Trevena Inc (NAS:TRVN)
$ 6.7 -0.79 (-10.55%) Market Cap: 5.71 Mil Enterprise Value: 26.50 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 23/100

Q1 2023 Trevena Inc Earnings Call Transcript

May 15, 2023 / 12:00PM GMT
Release Date Price: $29.5 (-12.59%)
Operator

Hello, and welcome to the Trevena, Inc. First Quarter 2023 Earnings Call. (Operator Instructions) Please note, today's event is being recorded.

I would now like to turn the conference over to Barry Shin, Chief Financial Officer. Please go ahead, sir.

Barry Shin
Trevena, Inc. - Senior VP & CFO

Thanks, Keith. Good morning, and welcome, everyone. With me today are Carrie Bourdow, our President and CEO; Patty Drake, our Chief Commercial Officer; and our Chief Medical Officer, Mark Demitrack.

As a reminder, OLINVYK was approved by the FDA in August 2020 and contains oliceridine, an opioid which is a Schedule II controlled substance with a high potential for abuse similar to other opioids. It's indicated in adults for the management of acute pain severe enough to require an IV opioid analgesic and for whom alternative treatments are inadequate. As with all opioids, serious, life-threatening or fatal respiratory depression may occur in patients treated with OLINVYK as indicated in the boxed warning. The important safety information, including

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot